FENTANYL CITRATE INJECTION SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

FENTANYL (FENTANYL CITRATE)

可用日期:

JAMP PHARMA CORPORATION

ATC代码:

N01AH01

INN（国际名称）:

FENTANYL

剂量:

50MCG

药物剂型:

SOLUTION

组成:

FENTANYL (FENTANYL CITRATE) 50MCG

给药途径:

INTRAMUSCULAR

每包单位数:

15G/50G

处方类型:

Narcotic (CDSA I)

治疗领域:

OPIATE AGONISTS

產品總結:

Active ingredient group (AIG) number: 0123302002; AHFS:

授权状态:

APPROVED

授权日期:

2020-10-23

产品特点

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
FENTANYL CITRATE INJECTION
Solution for injection
fentanyl 50 mcg / mL as fentanyl citrate
For epidural, intramuscular or slow intravenous administration
USP
Narcotic Analgesic
Adjunct to Anesthesia
Jamp Pharma Corporation
Date of Preparation: October 21, 2019
1310 rue Nobel
Boucherville, Québec,
Canada J4B 5H3
Submission Control No: 230156
_Fentanyl Citrate Injection. _
_Page 2 of 45_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
.........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
....................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................13
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................
17
OVERDOSAGE
.................................................................................................................
22
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 22
STORAGE AND STABILITY
..........................................................................................
26
SPECIAL HANDLING INSTRUCTIONS
........................................................................26
DOSAGE FORMS, COMPOSITION AND PACKAGING
..............................................26
PART II: SCIENTIFIC INFORMATION
................................................................................28
PHARMACEUTICAL INFORMATION
................